"Irish drug maker Elan Corp (Irish:ELN.I - News) reported second-quarter results broadly in line with expectations on Thursday and said it was on track to bring its flagship drug Antegren to market next year.

Former stock market star Elan has pulled back from a brush with bankruptcy in 2002 and is pinning its hopes on Antegren largely as a treatment for multiple sclerosis (MS), but also for the bowel disorder Crohn's Disease and rheumatoid arthritis.

"Antegren across three different indications, both in Europe and the U.S. marketplace, continues to make significant progress both in its timeframes and its deliverables," Chief Executive Kelly Martin told Reuters in an interview.

"There's a lot going on with Antegren, all good, all on time and all as committed to," he said.